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Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumour cells through activation of
TRAIL-R1 and TRAIL-R2 death signalling receptors. Here, we describe the characterisation and activity of HGS-ETR1, the first fully
human, agonistic TRAIL-R1 mAb that is being developed as an antitumour therapeutic agent. HGS-ETR1 showed specific binding to
TRAIL-R1 receptor. HGS-ETR1 reduced the viability of multiple types of tumour cells in vitro, and induced activation of caspase 8, Bid,
caspase 9, caspase 3, and cleavage of PARP, indicating activation of TRAIL-R1 alone was sufficient to induce both extrinsic and
intrinsic apoptotic pathways. Treatment of cell lines in vitro with HGS-ETR1 enhanced the cytotoxicity of chemotherapeutic agents
(camptothecin, cisplatin, carboplatin, or 5-fluorouracil) even in tumour cell lines that were not sensitive to HGS-ETR1 alone. In vivo
administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-
cell lung, and renal tumours in xenograft models. Combination of HGS-ETR1 with chemotherapeutic agents (topotecan, 5-
fluorouracil, and irinotecan) in three independent colon cancer xenograft models resulted in an enhanced antitumour efficacy
compared to either agent alone. Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum
concentrations were biphasic with a terminal half-life of 6.9–8.7 days and a steady-state volume of distribution of approximately
60mlkg
 1. Clearance was 3.6–5.7ml
 1day
 1kg
 1. These data suggest that HGS-ETR1 is a specific and potent antitumour agent
with favourable pharmacokinetic characteristics and the potential to provide therapeutic benefit for a broad range of human
malignancies.
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Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL), also known as Apo2L, is a member of the TNF ligand
superfamily (Wiley et al, 1995; Pitti et al, 1996). It induces
apoptosis in many cancer cell lines, with minimal to no effect on
most normal cells (Wiley et al, 1995; Pitti et al, 1996; Kothny-
Wilkes et al, 1998; Ashkenazi et al, 1999; Walczak et al, 1999;
Lawrence et al, 2001; Evdokiou et al, 2002). TRAIL mediates
apoptosis through two death receptors, TRAIL-receptor 1 (TRAIL-
R1, DR4, TNFRSF10A) and TRAIL-receptor 2 (TRAIL-R2,
DR5, TNFRSF10B). While additional receptor proteins that bind
TRAIL exist (TRAIL-R3/DcR1, TRAIL-R4/DcR2, Osteoprotegerin/
OPG), these receptors lack functional death domains and, as
such, do not initiate apoptosis (LeBlanc and Ashkenazi, 2003;
MacFarlane, 2003).
The TRAIL death receptor-induced apoptosis is mediated
through activation of both extrinsic and intrinsic intracellular
death signalling pathways. TRAIL binding to death receptors
results in formation of a death-inducing signalling complex
(DISC), consisting of death receptors, adaptor proteins, and
procaspase 8, which leads to processing and activation of
procaspase 8 by an autocatalytic mechanism (Sprick et al, 2000).
Activated caspase 8 triggers the extrinsic apoptotic pathway by
directly activating effectors such as caspase 3 and caspase 7,
resulting in cleavage of downstream targets such as poly (ADP-
ribose) polymerase (PARP). Caspase 8 can also initiate the
intrinsic apoptotic pathway through the activation of Bid.
Activated Bid induces oligomerisation of proapoptotic proteins
Bax and Bak, resulting in the release of both cytochrome c and
Smac/DIABLO from the mitochondria and subsequent activation
of caspase 9 (Srivastava, 2001; Ozoren and El-Deiry, 2003). Both
pathways lead to the activation of caspase 3 and eventual apoptotic
cell death.
TRAIL induces apoptosis in various tumour cell types in vitro and
in vivo. While TRAIL alone induces apoptosis in sensitive cancer
cell lines, TRAIL activity can be enhanced upon coexposure with
various chemotherapeutic agents (Gliniak and Le, 1999; Keane et al,
1999; Yamanaka et al, 2000; Bouralexis et al, 2001; Evdokiou
et al, 2002; Shimoyama et al, 2002). Tumour cells that are resistant
to TRAIL can be sensitised by combination treatment with
various chemotherapeutic drugs (LeBlanc et al, 2002). In vivo,t h e
antitumour efficacy of TRAIL in combination with chemotherapeu-
tic agents, such as 5-fluorouracil and irinotecan, was greater
than the activity of either agent alone (Gliniak and Le, 1999; Revised 27 January 2005; accepted 2 February 2005
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In addition to TRAIL, other methods of targeting TRAIL
receptors have been proposed as cancer therapeutics. Agonistic
TRAIL-R1 or TRAIL-R2 antibodies may have enhanced therapeu-
tic potential due to a prolonged half-life in vivo compared to
TRAIL ligand (Yagita et al, 2004). Proof of concept has been
demonstrated with murine or rabbit monoclonal antibodies
(mAbs) to human TRAIL-R1 or TRAIL-R2, which have antitumour
activity in vitro and in vivo (Griffith et al, 1999; Muhlenbeck et al,
2000; Chuntharapai et al, 2001; Ichikawa et al, 2001). Mech-
anistically, these agonistic antibodies work by activation of TRAIL
receptor-mediated apoptotic pathways in a manner similar to
TRAIL, as a TRAIL-R1 antibody induced PARP cleavage in B-cell
lymphoma 9D cells (Chuntharapai et al, 2001), and TRAIL-R2
antibodies induced activation of caspases and JNK/p38 kinase in
tumour cells (Ichikawa et al, 2001; Ohtsuka et al, 2003). Enhanced
apoptotic signalling and cell killing in vitro has been observed with
TRAIL-R1 and TRAIL-R2 antibodies in combination with chemo-
therapeutic agents (Ohtsuka et al, 2003). A murine TRAIL-R2
monoclonal antibody demonstrated inhibition of tumour growth
in a breast cancer xenograft model alone and in combination with
chemotherapeutic agents and radiation (Buchsbaum et al, 2003).
These results underscore the potential use of agonistic TRAIL-
receptor antibodies for cancer treatment; however, use of fully
human antibodies would be preferable for clinical applications to
avoid the immunogenicity associated with mouse and rabbit
antibodies (Berger et al, 2002).
Here, we describe the development and characterisation of
HGS-ETR1 (Mapatumumab), a fully human agonistic monoclonal
antibody with high affinity and specificity for TRAIL-R1.
HGS-ETR1 induced cell death in tumour cell lines and this killing
was mediated through the activation of both extrinsic and
intrinsic death signalling pathways. HGS-ETR1 was shown to have
a long half-life in vivo and suppressed the growth of colon, lung,
and renal tumours in xenograft models in athymic mice.
HGS-ETR1 also enhanced the antitumour efficacy of chemother-
apeutic drugs. These results show that HGS-ETR1 is a potent
antitumour agent either used alone or in combination with other
therapeutic drugs.
MATERIALS AND METHODS
Cell culture and reagents
Tumour cell lines Colo205, HCT116, H460, H2122, ST486, SW480,
RL95-2, SU.86.86, ES2, A498, WM793, and SNU398 (Park et al,
1995) were obtained from American Type Culture Collection
(ATCC, Rockville, MD, USA). JURL-MK1 tumour cell line was
obtained from Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DSMZ, German Collection of Microorganisms
and Cell Cultures, Mascheroder, Germany). TTn tumour cell line
was obtained from the Japanese Collection of Research Biore-
sources (JCRB Cell Bank, Tokyo, Japan). Tumour cell lines were
cultured and cell assays performed in media recommended by
supplier containing at least 10% serum. Chemotherapeutics
sources were: topotecan, Calbiochem (San Diego, CA, USA);
cisplatin, Bristol Myers-Squibb (Princeton, NJ, USA); irinotecan,
Pharmacia & Upjohn (Kalamazoo, MI, USA); 5-fluorouracil (5FU),
American Pharmaceutical Partners, Inc. (Schaumburg, IL, USA);
and carboplatin and camptothecin, Sigma (St Louis, MO, USA).
Selection and generation of a TRAIL-R1 agonist
monoclonal antibody
Phage display was used to isolate anti-TRAIL-R1 antibodies. A
large nonimmunised human scFv (single chain variable fragment)
phage display library was used for selection as described
previously (Marks et al, 1991). Human soluble extracellular
domain (ECD) TRAIL-R1-flag fusion protein at 10mgml
 1 in
PBS was immobilised onto immunotubes (Nunc, Rochester, NY,
USA) overnight at 41C. Three or four rounds of panning selections
were performed using the scFv human antibody phage library with
approximately 1.4 10
10 individual recombinants (Vaughan et al,
1996). A deselection round was performed on an irrelevant fusion
protein to remove any nonspecific binders. From this process, a
panel of 1500 clones were selected and screened by ELISA for
binding to TRAIL-R1. Screening of clones by ELISA has been
described previously (Jackson et al, 1992). A total of 250 scFvs
were identified that bound to TRAIL-R1, but did not bind to an
irrelevant fusion protein. DNA sequence analysis of this panel
identified 102 unique scFvs. Candidate scFvs were further selected
from this panel based on agonistic activity in viability assays of
SW480 and HeLa cells. The scFvs with the highest activity,
including HGS-ETR1, were converted to IgG1, expressed in an
NSO mouse myeloma cell line, secreted into culture media, and
purified by a series of standard chromatography steps.
ELISAs
To determine direct binding of fully human IgG1 HGS-ETR1 to
TRAIL-R1, TRAIL-receptor extracellular domain fusion proteins
(TRAIL-R1, -R2, -R3, -R4) were immobilised on 96-well plates, and
various concentrations of HGS-ETR1 (0.9–66.7nM) were added.
After incubation for 2h at room temperature, the wells were
washed and bound HGS-ETR1 antibody was detected using
peroxidase-conjugated goat anti-human IgG Fab and tetramethyl-
benzidine (TMB) horseradish peroxidase (HRP) substrate solution
(KPL, Gaithersburg, MD, USA) according to the manufacturer’s
instructions.
Flow cytometry
Adherent cell lines were detached from flasks using EnzFree buffer
(Quality Biological, Gaithersburg, MD, USA), washed with FACS
buffer (PBS with 0.1% NaN3 and 0.1% BSA) and resuspended at 10
6
cells per 100ml. Cell surface expression of TRAIL receptors was
determined using 10mgml
 1 (final concentration) of HGS-ETR1 or
commercial mouse anti-TRAIL-R1 antibodies (eBiosciences, San
Diego, CA, USA). Matched isotype control human IgG (IC mAb) or
commercial mouse IgG (eBiosciences) monoclonal antibodies were
used as negative controls. Cells were incubated with antibodies for
20min at room temperature, washed, resuspended in 200ml FACS
buffer containing 0.5mgml
 1 propidium iodide and analysed on a
FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). To
determine specificity of HGS-ETR1 binding, FACS analysis was
performed in the presence of 5mgml
 1 of soluble TRAIL receptor-
Fc fusion proteins (R&D Systems, Minneapolis, MN, USA).
Viability assays
Cell viability was determined using Cell Titer-Glo (Promega,
Madison, WI, USA). Cells were plated in 96-well white polystyrene
opaque plates (Costar/Corning, Acton, MA, USA) and incubated
overnight at 371C. Indicated concentrations of HGS-ETR1
antibody or controls were added. In combination studies, che-
motherapeutic agents were also added at the indicated concentra-
tions with either control antibody or HGS-ETR1. After 48h
incubation, cell viability was measured according to the manufac-
turer’s instructions. In brief, 100ml of assay reagent was added to
cells at room temperature, mixed and incubated for approximately
30min. Luminescent signal was read using a Northstar luminescent
plate reader. All treatments were performed in triplicate. The
average and standard deviation were determined and data plotted
using Prism software (GraphPad Software, San Diego, CA, USA).
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Cells were plated in black-walled 96-well plates (Costar) at 1 10
4
cells well
 1 and cultured overnight. Cells were treated with
HGS-ETR1 or controls for the indicated times at 371C and caspase
activity was measured using a tagged caspase substrate (rhoda-
mine-labeled DEVD peptide). The assay was performed according
to the manufacturer’s instructions (Apo-ONE Homogeneous
Caspase 3/7 Assay, Promega) and the release of the fluorogenic
moiety by activated caspases was measured by reading plates at
405nm using a fluorometric plate reader. Treatments were
performed in triplicate and the average and standard deviation
determined and plotted.
Western blot analysis
Cells (2 10
6) were plated overnight in a 150-mm cell culture plate
and then treated with the indicated concentrations of HGS-ETR1
or control antibody for 4h at 371C in a cell culture incubator. Cells
were then scraped in ice-cold PBS, centrifuged and cell pellets
lysed with 1% NP40 lysis buffer (10mM HEPES pH 7.5, 0.15mM
NaCl, 10% glycerol, protease inhibitors cocktail and 1mM PMSF).
The protein concentration of the lysates was determined by BCA
method (Pierce, Rockford, IL, USA) and normalised with lysis
buffer. The proteins were separated using Tris-glycine polyacry-
lamide SDS gel electrophoresis and transferred to nitrocellulose
membranes (Invitrogen, San Diego, CA, USA). The filters were
incubated with antibodies that recognise the pro and cleaved forms
of the apoptotic proteins PARP (Pharmingen, San Diego, CA,
USA), caspase 3, caspase 8, caspase 9 (Upstate Biotechnology Inc.,
Lake Placid, NY, USA), Bid (Cell Signaling, Beverly, MA, USA), and
actin (Santa Cruz, Santa Cruz, CA, USA). The bands corresponding
to specific proteins were detected by HRP-conjugated secondary
antibodies and enhanced chemiluminescence (Amersham Corp.,
Piscataway, NJ, USA).
In vivo tumour models
For pre-established xenograft tumour models (Colo205, HCT116,
H2122, and A498), female Swiss athymic mice (Taconic, German-
town, NY, USA), 7–8 weeks of age and 20g average body weight,
were used. All experiments were performed in accordance with the
current guidelines established by UKCCR and the Institutional
Animal Care and Use Committee at Human Genome Sciences Inc.
On day 0, 1 10
7 tumour cells were injected subcutaneously (s.c.)
in the lower right flank of the mouse (H2122, Colo205, A498,
HCT116). Prior to any treatments, tumours were grown to
B100mm
3 and 8–10 mice per group were used for each treatment
group. In the single-agent models, HGS-ETR1 or isotype control
antibody was administered to the animals intravenously (i.v.) via
tail vein in a dose/weight-matched fashion on indicated days.
Tumours were established as above for the Colo205 and HCT116
combination treatment models. In the Colo205 combination
model, 5FU mini-pumps were inserted on day 7. Each 0.5mlh
 1
mini-osmotic pump (Alzet Osmotic Pumps, Durect Corporation,
Cupertino, CA, USA) was filled with sterile 5FU solution (50mg
5FUml
 1 water, pH 9.0) for a 1.25mgkg
 1h
 1 flow rate. Mice
were anesthetised with inhaled isoflurane, skin was sterilised and
the mini-osmotic pumps containing 5FU were inserted s.c. in a
pocket formed dorsally under the skin of the mouse. Skin was
closed with two 9mm wound clips. Wound clips were removed
after 14 days. Continuous infusion of 5FU was given from days
7–21. Isotype control antibody (10mgkg
 1) was administered i.v.
on days 7, 10, 12, 14, 17, 19, 21, 24, 26, 28, and 31. HGS-ETR1
(10mgkg
 1) was administered i.v. on days 14, 17, 19, 21, 24, 26, 28,
and 31 either alone or in animals treated with 5FU. One group of
animals was untreated. In the HCT116 combination treatment
model, HGS-ETR1 or isotype control antibody (10mgkg
 1) was
administered i.v. on days 11, 17, and 24. Irinotecan was
administered i.p. at a dose of 8mgkg
 1 on days 11, 15, 17, 21,
24, and 28. For the SW480 combination treatment de novo model,
male Swiss athymic mice (Taconic), 6–8 weeks of age and 20–25g
average body weight, were used and 1 10
7 SW480 cells were
injected per site, six mice per group on day 0. On day 1, a loading
dose of HGS-ETR1 (20mgkg
 1) was administered i.v.. Topotecan
was administered i.p. at a dose of 0.3mgkg
 1 on days 1–3. Subse-
quently, HGS-ETR1 (10mgkg
 1) and topotecan (0.3mgkg
 1) were
administered i.p. on days 4, 7, 10, 13, and 16. One group of mice
was injected with vehicle control. For all models, tumour size on
two axes was measured with digital calipers at 3–4-day intervals.
The values were transformed into tumour volumes using the
following formula: tumour volume¼0.5 width
2 length. Un-
paired Student t-tests were used to evaluate the significance of
differential tumour growth. The difference was considered
significant when P was o0.05.
In vivo pharmacokinetics
Male BALB/c mice (8 weeks old, 21–25g) were obtained from Ace
Animals (Boyertown, PA, USA). Mice were injected i.v. via tail vein
with 10 or 20mgkg
 1 HGS-ETR1. Four mice were injected for each
time point. Mice were killed and blood was collected at 5min, 3h,
8h, 1, 2, 3, 4, 7, and 10 days postinjection. Sera prepared from the
blood samples were stored at  801C until analysed by ELISA. For
the ELISA assays, a Maxisorb plate (Nalge Nunc International,
Rochester, NY, USA) was coated with a TRAIL-R1 fusion protein
solution (2mgml
 1 in PBS), and blocked with a PBS solution
containing 10% goat serum. The sera samples to be tested for
HGS-ETR1 levels were diluted 2000-fold (0.05%) in a PBS solution
containing 0.05% Tween-20. HGS-ETR1 standards and positive
controls were made in a PBS solution containing control 0.05%
BALB/c serum. Diluted samples, standards, and positive controls
were incubated on the plate for 2h at room temperature. The
plate was washed six times using a PBS solution containing 0.1%
Tween-20 and incubated for 2h with a PBS solution of 10% goat
sera containing HRP-labelled anti-human lIgG antibody
(1:80000). The plate was washed once more prior to the addition
of TMB HRP substrate. After a 15-min development time, the HRP
activity was terminated using dilute sulphuric acid and the
relative absorbance at 450nm was measured using a Spectromax
ELISA (Molecular Devices, Sunnyvale, CA, USA) plate reader. The
concentration of the HGS-ETR1 in the sera samples was
extrapolated from the HGS-ETR1 standard curve. The limit of
quantitation of the assay is 5ngml
 1 in 100% serum. To obtain
pharmacokinetic parameters, serum concentration data were
fitted with a two-compartment i.v. bolus model with 1/(predicted
value)
2 weighting using the software package WinNonlin (Phar-
sight Corp., Mountain View, CA, USA). Data from all mice in each
dose group were fit together to obtain a pooled estimate of the PK
parameters.
RESULTS
HGS-ETR1 binds specifically to human TRAIL-R1
TRAIL-R1-specific scFv antibodies were isolated from human
phage display libraries based on their binding to a TRAIL-R1
extracellular domain fusion protein. A panel of 102 unique anti-
TRAIL-R1 scFv antibodies was further screened for inhibition of
TRAIL binding to TRAIL-R1 and for cytotoxic effects on HeLa cells
(data not shown). Several top candidates were converted to IgG1
and further characterised for agonist activity on multiple tumour
cell types and antitumour activity in xenograft models. HGS-ETR1
was selected as the lead candidate based on its potent in vitro and
in vivo antitumour effects. Binding of the fully human IgG1 form of
Agonistic TRAIL-R1 mAb
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proteins immobilised on 96-well plates was characterised using an
ELISA format. Specific binding of HGS-ETR1 to the TRAIL-R1
protein but not to other TRAIL receptors was observed
(Figure 1A). The specificity of HGS-ETR1 binding and activity
was also analysed in cell-based assays. Binding of HGS-ETR1 to
TRAIL-R1 on the surface of SW480 tumour cells was detected
by flow cytometry. HGS-ETR1 binding was specific for TRAIL-R1
as only soluble TRAIL-R1-Fc protein, but not other soluble
TRAIL receptors, blocked binding (Figure 1B). Agonistic activity
of HGS-ETR1 was shown in in vitro tumour cell viability
assays where significant cell death occurred after a 48-hour
treatment of SW480 cells with HGS-ETR1. No loss of viability was
observed by treatment with an isotype control antibody. Addition
of soluble TRAIL-R1, but not soluble TRAIL-R2, TRAIL-R3,
TRAIL-R4 or OPG, blocked killing of SW480 cells by HGS-ETR1
(Figure 1C).
HGS-ETR1 reduces viability and activates apoptotic
signalling in human tumour cell lines
HGS-ETR1 induction of cell killing and mechanism of action were
analysed in multiple tumour cell lines (SW480, Colo205, HCT116,
H2122, H460, SU.86.86, RL95-2, ST486, JURL-MK1, A498, SNU398,
and WM793), representing various tumour types (Table 1). All of
the cell lines, with the exception of the WM793 melanoma cell line,
expressed detectable levels of cell surface TRAIL-R1 by FACScan
analysis (Table 1). Treatment with various concentrations of HGS-
ETR1 resulted in a dose-dependent reduction of cell viability at
48h (Figure 2A) preceded by activation of caspase 3/7 at 6h
(Figure 2B) in most cell lines. Sensitivity to HGS-ETR1 varied
among these cells. For example, HGS-ETR1 treatment substantially
decreased viability of ST486, and SW480, whereas H460 and
HCT116 showed lesser sensitivity to HGS-ETR1-induced killing.
HGS-ETR1 induced apoptotic signalling as measured by caspase
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Figure 1 Characterization and specificity of HGS-ETR1 antibody. (A) Direct-binding ELISA data show the binding of indicated concentrations of
HGS-ETR1 to the TRAIL-R1 extracellular domain Fc-protein (filled circles) or other TRAIL-R extracellular domain Fc-proteins (open symbols) immobilised
on 96-well plates. Binding of HGS-ETR1 to TRAIL-receptors was detected using anti-human Fab-peroxidase conjugate. (B) Binding of HGS-ETR1 to SW480
cells analysed by flow cytometry. The top panel shows the binding of isotype control monoclonal antibody (IC mAb, dotted line) and HGS-ETR1 (shaded
peak). The bottom panels show the binding of HGS-ETR1 alone (shaded peak) or binding of HGS-ETR1 in presence of 5mgml
 1 of the indicated soluble
TRAIL-R Fc-protein (solid line). (C) For viability assays, SW480 cells were plated at 1 10
4 cells well
 1 in a 96-well plate and cultured overnight. A
1mgml
 1 concentration of HGS-ETR1 or isotype control monoclonal antibody (IC mAb) was added to the cells in the absence or presence of the indicated
soluble TRAIL-receptor proteins (sTRAIL-R1-4, sOPG, 5mgml
 1) and cell viability, measured as relative light units (RLU), was determined after 48h. Data is
the mean7s.d. of triplicate samples.
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treatment. HGS-ETR1 did not induce caspase activity or reduce
cell viability in WM793 or SNU-398 cells.
To more fully characterise the signalling pathways used by
HGS-ETR1, activation of intracellular apoptotic signalling mole-
cules was determined by Western analysis in three cell lines. Dose-
dependent activation of caspases, as determined by a decrease in
procaspase 8 levels and cleavage of caspase 9 and caspase 3, was
observed after a 4-h treatment of ST486 and SW480 cell lines with
HGS-ETR1 (Figure 2C). HGS-ETR1 treatment also resulted in
cleavage of Bid, a substrate of caspase 8, and PARP, a substrate of
caspase 3. The activation of these pathways by HGS-ETR1 was
clearly evident in ST486 and SW480. In contrast, in HCT116 cells,
minimal activation of death signalling proteins was detected at
high concentrations of HGS-ETR1 (Figure 2C).
HGS-ETR1 enhancement of chemotherapeutic agent
activity in vitro
Combination treatment of HGS-ETR1 with chemotherapeutic
agents in vitro was analysed in HGS-ETR1-sensitive (HCT116
colon, H460 NSCLC) and -insensitive (ES2 ovarian, and TTn
oesophageal) tumour cell lines. Cells were treated with various
concentrations of control antibody or HGS-ETR1 either alone or in
combination with camptothecin (HCT116), cisplatin (H460),
carboplatin (ES2), or 5-fluorouracil (TTn) and the cell viability
was determined after 48h (Figure 3). Chemotherapeutic drug
concentrations were used that had been previously established to
give approximately 50% cell killing by drug alone (data not
shown). In each case, the treatment with HGS-ETR1 plus
chemotherapeutic drug resulted in enhanced cell killing, which
was greater than the effect of either agent alone. Combination
treatment substantially enhanced chemotherapeutic drug cytotoxi-
city even in two cell lines (TTn and ES2) where HGS-ETR1
treatment alone did not decrease cell viability, suggesting a
synergistic interaction between HGS-ETR1 and the chemother-
apeutic agents.
HGS-ETR1 reduces the growth of human tumours in
xenograft models
HGS-ETR1 in vivo antitumour activity was evaluated in NSCLC
(H2122), colon (Colo205), and renal (A498) tumours in xenograft
models in athymic nude mice. Tumours were pre-established s.c.
to a volume of approximately 100mm
3 before initiation of
antibody treatments. Three weekly treatments of HGS-ETR1 at a
concentration of 2.5 or 10mgkg
 1 showed strong single-agent
antitumour activity in the H2122 NSCLC xenograft model, with
significant tumour regression observed after a single injection of
HGS-ETR1 (Figure 4, Po0.0001). Tumour volume was reduced
approximately 50% by day 10, 4 days after the first injection of
HGS-ETR1 and by day 25, there was a 97% reduction in tumour
volume for the 10mgkg
 1 dose of HGS-ETR1. In addition, tumour
regrowth was suppressed for several weeks after termination of
HGS-ETR1 treatment (data not shown). HGS-ETR1 also induced
tumour regression in colon and renal xenograft tumour models.
Treatment with a 10mgkg
 1 dose of HGS-ETR1, every other day
or once a week, respectively, dramatically reduced tumour
volumes in Colo205 colon (Po0.0001 at day 21) and A498 renal
(Po0.0001 at day 28) xenograft tumour models compared to the
isotype control antibody (Figure 4).
The ability of HGS-ETR1 to enhance the in vivo antitumour
activity of three different chemotherapeutic agents was tested in
three independent colon xenograft models (Figure 5). HGS-ETR1
in combination with 5FU was tested in the Colo205 xenograft
model (Figure 5A). Tumours of approximately 100mm
3 were
pre-established, and animals were treated with 5FU alone
(continuous infusion mini-pump, 1.25mgkg
 1h
 1, days 7–21),
HGS-ETR1 alone (i.v., 10mgkg
 1, days 14, 17, 19, 21, 24, 27, 29,
and 31), or combination of 5FU and HGS-ETR1, and compared
to no treatment or treatment with isotype control mAb (i.v.,
10mgkg
 1, days 7–31). Tumour size in nontreated animals was
not significantly different from isotype control mAb treated.
Both 5FU alone (Po0.001) and HGS-ETR1 alone (Po0.001)
had a significant cytostatic effect on tumour growth compared
to control. For the HGS-ETR1þ5FU combination treatment
group, mice were pretreated with 5FU for 7 days before treat-
ment with HGS-ETR1 and resulted in an immediate decrease
in tumour volume evident at day 17. The overall effect on
tumour volume after combining HGS-ETR1 and 5FU was
significantly different when compared to either agent alone
(Po0.001).
The effect of combination of HGS-ETR1 with irinotecan was
examined in pre-existing HCT116 colon tumours (Figure 5B).
Tumours of approximately 100mm
3 were established and animals
were treated with irinotecan (i.p., 8mgkg
 1), HGS-ETR1 (i.v.,
10mgkg
 1), or isotype control antibody (i.v., 10mgkg
 1). At day
31, treatment with irinotecan alone resulted in a 38.8% reduction
in tumour growth compared to control antibody (Po0.0113).
HGS-ETR1 treatment showed a 20.1% reduction in tumour
volume, which was not significantly different from that of the
control antibody group (Po0.2248). The combination of
HGS-ETR1 plus irinotecan resulted in a significant reduction of
tumour growth (59.7%) when compared with control antibody
Table 1 TRAIL-R1 and TRAIL-R2 cell surface expression on tumour cell lines
Cell line Tumour type TRAIL-R1 expression TRAIL-R2 expression
SW480 Colon adenocarcinoma 3.471.3 5.972.0
H2122 Non-small-cell lung carcinoma 3.170.2 7.170.3
A498 Renal cell carcinoma 2.771.2 6.471.1
ST486 Burkitt’s lymphoma 1.970.1 0.670.2
Colo205 Colon adenocarcinoma 1.870.6 7.472.1
SU.86.86 Pancreatic ductal carcinoma 1.870.4 2.970.2
H460 Non-small-cell lung carcinoma 1.770.5 4.071.0
SNU-398 Hepatocellular carcinoma 1.670.2 3.270.0
TTn Oesophageal squamous carcinoma 1.4570.4 1.070.3
HCT116 Colon adenocarcinoma 1.470.2 3.470.9
JURL-MK1 Chronic myeloid leukaemia 1.1570.1 2.670.5
RL95-2 Uterine endometrial carcinoma 1.270.2 1.970.2
ES2 Ovarian clear cell carcinoma 1.170.1 4.971.7
WM793B Melanoma 1.070.09 10.270.5
TRAIL-R1 and TRAIL-R2 expression was determined by FACs analysis and is expressed as the fold-increase in mean fluorescent signal of commercial mouse TRAIL-R1 or R2
antibody vs isotype control antibody. The data is the average7s.d. from two or more experiments.
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(Po0.007).
The effect of HGS-ETR1 and topotecan alone or in combination
was tested in a de novo SW480 colon tumour cell model
(Figure 5C). On day 1, 24h after SW480 tumour cell implantation,
a loading dose of HGS-ETR1 (20mgkg
 1) was administered i.v.
Topotecan (0.3mgkg
 1) was administered i.p. on days 1, 2, and 3.
Topotecan and HGS-ETR1 (10mgkg
 1) alone or in combination
were administered i.p. on days 4, 7, 10, 13, and 16. At day 28, when
compared to vehicle control, topotecan alone did not show a
significant effect (19.2% reduction in tumour volume; Po0.349),
but HGS-ETR1 treatment alone (51.5% reduction; Po0.040), or
coadministration of HGS-ETR1 and topotecan (70.7% reduction;
Po0.007), significantly inhibited the growth of SW480 tumours.
The reduction of tumour growth by the combination of HGS-ETR1
plus topotecan was significantly greater than topotecan alone
(Po0.0194); however, significance was not reached when the
combination was compared to HGS-ETR1 alone (Po0.0907).
Pharmacokinetics of HGS-ETR1 in normal BALB/c mice
following a single intravenous injection
The pharmacokinetics of HGS-ETR1 was evaluated in Balb/c mice
following a single i.v. injection of 10 or 20mgkg
 1. Serum
concentrations of HGS-ETR1 were determined by ELISA (Figure 6).
The solid line shows a fit of a two-compartment pharmacokinetic
model to the serum concentration data. Pharmacokinetic para-
meters are listed in Table 2. The beta, or elimination, phase
contributes approximately 98% of the total area under the curve.
The terminal half-life (t1/2, b) of HGS-ETR1 in mice is 6.9–8.7 days,
the clearance is 4.81–5.66mlday
 1kg
 1, and the steady-state
volume of distribution (Vss) is 55.3–59.0mlkg
 1. The Cmax and
AUC are approximately proportional to dose. The t1/2, b, CL, Vi,
and Vss are not significantly different between dose groups,
indicating that the pharmacokinetics of HGS-ETR1 were linear
over the limited range of doses tested.
DISCUSSION
Engagement of cell surface death receptors by TRAIL is the initial
step in the induction of intracellular death signalling pathways and
apoptosis (Srivastava, 2001; Ozoren and El-Deiry, 2003). Mouse
agonistic mAbs generated against human TRAIL-R1 and
TRAIL-R2 also induce apoptosis in human tumour cells (Ichikawa
et al, 2001; Ohtsuka et al, 2003; Yagita et al, 2004). In this report,
we examine the activity of HGS-ETR1, a fully human TRAIL-R1
agonistic mAb, and our results confirm and extend these previous
observations. HGS-ETR1 bound specifically to TRAIL-R1 on the
surface of human tumour cells and induced apoptosis of diverse
tumour types. The WM793B melanoma cell line lacked measurable
cell surface TRAIL-R1 expression and did not show sensitivity to
HGS-ETR1. Despite the very high levels of TRAIL-R2 expression
on this cell line, HGS-ETR1 was unable to affect WM793B cell
viability. This data and the specific binding of HGS-ETR1 to
TRAIL-R1 support the theory that HGS-ETR1 activity is mediated
only through TRAIL-R1. In the cell lines in which HGS-ETR1
induced cell death, HGS-ETR1 also triggered caspase activation,
indicating that induction of apoptosis is the primary mechanism
through which HGS-ETR1 kills tumour cells. HGS-ETR1 induced
activation of both the extrinsic pathway, as demonstrated by
caspase 8 activation, and the intrinsic pathway as evidenced by
caspase 9 activation, showing that specific activation of the
TRAIL-R1 death receptor can lead to signalling though both
apoptotic pathways. The activation of these cell death cascades led
to measurable and concomitant activation of the executioner or
terminal caspase 3. The use of a TRAIL-R1-specific high-affinity
mAb demonstrated that TRAIL-R1 can mediate a dominant and
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Figure 2 HGS-ETR1 induces tumour cell killing and apoptotic signalling. (A) SW480, Colo205, HCT116, H2122, H460, SU.86.86. RL95-2, ST486, JURL-
MK1, A498, SNU398, and WM793B cells were plated in 96-well plates at approximately 1 10
4 cells well
 1, and cultured overnight. Indicated
concentrations of HGS-ETR1 (closed circles), or isotype control antibody (IC mAb, open squares) were added and cell viability, measured as relative light
units (RLU), was determined after 48h. (B) Cells were treated as in viability assays (ngml
 1) and caspase 3/7 activity was measured as relative fluorescent
units (RFU) after 6h of treatment. The viability and caspase data are the mean7s.d. of triplicate samples from matching representative experiments. (C)
ST486, SW480, and HCT116 cells were plated on 100-mm plates, cultured overnight and indicated concentrations of HGS-ETR1 or isotype control
antibody (10mgml
 1) were added. After 4h of treatment, cell lysates were prepared, normalised for protein concentration and Western analysis was
performed. The actin protein levels are shown as a control for protein loading.
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that there is a preferential activation of TRAIL-R2 for the
induction of apoptosis (Kelley et al, 2005).
Although TRAIL-R1 cell surface expression was required for the
cytotoxic activity of HGS-ETR1, TRAIL-R1 expression levels did
not predict the level of sensitivity. In general, a higher expression
of TRAIL-R1 was seen in the most sensitive cell types; however, we
found that there are cell lines in which there is a divergence
between receptor level and HGS-ETR1 activity. For example, some
cells with lower levels of TRAIL-R1 (RL95-1) were eliminated to a
greater extent than cells with higher TRAIL-R1 expression (H460
or TTn). Additionally, one cell line (SNU398) with strong
TRAIL-R1 cell surface expression staining was completely resistant
to HGS-ETR1. Similar divergent responses in cell viability and cell
surface TRAIL death receptor levels were demonstrated for TRAIL
(Keane et al, 1999; Srivastava, 2001; Jang et al, 2003; Song et al,
2003), and variations in sensitivity of glioma cell lines to an anti-
TRAIL-R2 mAb were not correlated with TRAIL-R2 protein
expression (Kaliberov et al, 2004). The reason for this spectrum
of response to TRAIL-R activation is due to the complex
downstream regulation of the cell death pathway. Intracellular
levels of pro- and antiapoptotic factors such as cFLIP (Kim et al,
2000; Sayers et al, 2003), XIAP (Zhang et al, 2001; Chawla-Sarkar
et al, 2002), BCL-2 family members (Burns and El-Deiry, 2001;
LeBlanc et al, 2002), and DISC formation and caspase 8 activity
(Trauzold et al, 2003) have been reported to regulate cell
sensitivity to TRAIL-induced programmed cell death in both
tumour and normal cells. Although TRAIL decoy receptors have
been implicated in the regulation of TRAIL signalling, the presence
of decoy receptors (DcR1, DcR2) are not a factor in resistance to
HGS-ETR1 activity, as HGS-ETR1 does not bind to either of these
receptors (Figure 1). The levels and activity of pro- and
antiapoptotic intracellular factors, in addition to the levels of
TRAIL-R1 receptor, will influence the ability of HGS-ETR1 to
induce apoptosis in a given cell line. Further work will be needed
to identify the key factors that contribute to tumour cell sensitivity
to HGS-ETR1.
In vivo, HGS-ETR1 had potent antitumour activity in pre-
established colon, lung, and kidney xenograft cancer models. In
these experiments, HGS-ETR1 was administered at 2- or 7-day
intervals; given the half-life of HGS-ETR1 in mice (B5–7 days), we
would expect HGS-ETR1 to accumulate using these schedules. The
tumour regression observed in these models demonstrated that
these treatments were pharmacodynamically effective. HGS-ETR1
was highly active in the H2122 NSCLC model and induced a rapid
decrease in tumour volume after a single injection of HGS-ETR1
(2.5 or 10mgkg
 1), eliciting significant tumour regression.
Tumour regrowth was repressed for 20 days after the last
HGS-ETR1 treatment, suggesting that the effects of HGS-ETR1
on tumour cell growth can extend beyond the treatment phase. The
lack of tumour regrowth could be attributed to several factors
including activity of the residual HGS-ETR1, and the significant
loss of tumour cell number, tumour burden, and tumour
vasculature during the initial tumour regression. HGS-ETR1 alone,
at a concentration of 10mgkg
 1, also dramatically reduced
tumour volume in the Colo205 colon and A498 renal models
demonstrating that HGS-ETR1 had strong antitumour activity in
multiple, diverse tumour types.
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Figure 3 Combination of HGS-ETR1 with chemotherapeutic agents enhances tumour cell killing in vitro. HCT116, H460, ES2, and TTn cells were plated
in 96-well plates at approximately 1 10
4 cells well
 1 and cultured overnight. Indicated concentrations of HGS-ETR1 (closed circles), isotype control
antibody (IC mAb, open upward triangles); HGS-ETR1 plus indicated chemotherapeutic drug (closed squares), or IC mAb plus chemotherapeutic drug
(open downward triangles) were added and cell viability, measured as relative light units (RLU), was determined after 48h of treatment. Data are the
mean7s.d. of triplicate samples.
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sAs cancer therapy in the clinic often involves the use of multiple
therapeutic regimens, it was of interest to determine if HGS-ETR1
in combination with commonly used anticancer agents could
enhance HGS-ETR1 activity in vitro and in vivo. Previous
studies have shown that chemotherapeutic agents enhance
TRAIL-induced cell killing of various tumour cells in vitro and
in vivo (Naka et al, 2002; Arizono et al, 2003; Ray and Almasan,
2003; Singh et al, 2003). Combination treatment with chemo-
therapeutic agents in vitro also enhance murine TRAIL-R1 and
TRAIL-R2 agonistic antibody-induced cell killing (Ohtsuka et al,
2003), and combination of a murine TRAIL-R2 antibody with
adriamycin or paclitaxel showed greater inhibition of tumour
growth compared to antibody alone in a breast cancer model in
vivo (Buchsbaum et al, 2003).
Combination of HGS-ETR1 with different chemotherapeutic
agents in in vitro assays using HCT116 and H460 cells resulted in
enhanced cell killing compared to HGS-ETR1 or drug alone. In two
cell lines (ES2 and TTn), substantial enhancement of carboplatin-
or 5FU-induced cytotoxicity was observed after cotreatment
with HGS-ETR1, even in the absence of detectable activity of
HGS-ETR1 alone, demonstrating a synergistic interaction between
HGS-ETR1 and these chemotherapeutic agents. In vivo, enhanced
efficacy of combination treatments of HGS-ETR1 with three
different chemotherapy agents was demonstrated in three separate
colon xenograft tumour models. In the Colo205 model, 5FU
was given for 7 days via infusion, prior to HGS-ETR1 treatment
to emulate a current therapeutic delivery mode for 5FU in
colon cancer. Combination of HGS-ETR1 treatment with 5FU
pretreatment was effective in inducing a pronounced tumour
regression, suggesting that combination of chemotherapy and
HGS-ETR1 do not have to be given concurrently for efficacy.
Interestingly, this regression occurred immediately after injection
of HGS-ETR1, suggesting that the antitumour action of the
mAb to induce apoptosis and reduce tumour volume is rapid.
Various mechanisms have been proposed for the enhanced
cell death observed by combination of chemotherapy with
TRAIL, including upregulation of TRAIL-R1 and TRAIL-R2
(Bouralexis et al, 2001, 2003; Nimmanapalli et al, 2001; Singh
et al, 2003), increased levels of the proapoptotic protein,
Bak (LeBlanc et al, 2002) and suppression of prosurvival path-
ways (Asakuma et al, 2003). We have initiated experiments to
investigate the mechanisms responsible for the enhancement
of antitumour activity by HGS-ETR1 in combination with
chemotherapeutic agents.
The pharmacokinetic profile of HGS-ETR1 indicated that the
half-life of HGS-ETR1 was 6.9–8.7 days. For comparison, the
reported half-life of the TRAIL ligand that binds both TRAIL-R1
and TRAIL-R2 is 3.6min in mice (Kelley et al, 2001). The terminal
half-life of the HGS-ETR1 fully human monoclonal antibody is
similar to the 6–8-day half-life in mice reported for endogenous
IgG2a (Viera and Rajewsky, 1988) and the 6-day half-life in nude
mice reported for humanised IgG1 monoclonal antibodies against
VEGF or TAG-72 (Kashmiri et al, 1995; Lin et al, 1999). HGS-ETR1
showed a clearance of 4.81–5.66mlday
 1kg
 1, and the Vss was
approximately 60mlkg
 1. This indicates that HGS-ETR1 does
distribute to tissues, as the Vss represents a space greater
than plasma volume (40mlkg
 1), although it is restricted to a
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Figure 4 HGS-ETR1 represses the growth of lung, colon, and renal
tumours in vivo. Athymic mice were injected s.c. at day 0 with H2122 (A),
Colo205 (B), or A498 (C) tumour cells. After tumours had reached
approximately 100mm
3, mice were administered isotype control mono-
clonal antibody (IC mAb, open squares) or HGS-ETR1 (circles) by i.v.
injection at the indicated times (arrows) and doses. Eight to 10 mice were
included in each group. Each time point represents the mean value
(7s.e.m.) of the tumour sizes within the treatment group on the day of
measurement.
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sspace less than the total extracellular fluid volume of 170mlkg
 1
(Levine, 1990).
Overall, we have shown that HGS-ETR1, the first reported fully
human agonistic TRAIL-R1 mAb, specifically and exclusively
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Figure 5 Enhanced antitumour effect by combination of chemother-
apeutic agents and HGS-ETR1. Athymic mice were injected s.c. on day 0
with tumour cells. For the Colo205 and HCT116 models, tumours were
allowed to grow to approximately 100mm
3 before treatment. Chemo-
therapeutic agents, isotype control monoclonal antibody (IC mAb), or
HGS-ETR1 were administered at the indicated times (arrows) and
concentrations. Eight to 10 mice were included in each group. For the
SW480 de novo model, a loading dose of HGS-ETR1 (20mgkg
 1) was
administered i.v. on day 1. Topotecan was administered i.p. at a dose of
0.3mgkg
 1 on days 1–3. Subsequently, HGS-ETR1 (10mgkg
 1) and
topotecan (0.3mgkg
 1) were administered i.p. on days 4, 7, 10, 13, and 16.
One group of control mice was injected only with vehicle control. Six mice
were included in each group. For all models, each time point represents the
mean value (7s.e.m.) of the tumour sizes within the treatment group on
the day of measurement.
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Figure 6 Pharmacokinetics of HGS-ETR1 in mice. Serum concentrations
of HGS-ETR1 were determined in BALB/c mice following i.v. injection of 10
or 20mgkg
 1. Male BALB/c mice were injected i.v. with either 10 or
20mgkg
 1 HGS-ETR1, and serum concentrations were followed for 10
days. Data points are the mean (7s.d.) and solid lines represent the fit of a
two-compartment pharmacokinetic model to the data.
Table 2 Pharmacokinetic parameters following IV injection of HGS-
ETR1 in BALB/c mice (mean7s.e.m.)
Parameter 10mgkg
 1 20mgkg
 1 P-value
AUC (day mgml
 1) 20807175 35317287 N/A
AUC per dose (day kgml
 1) 0.28070.018 0.17770.014 0.1702
% AUCb (%) 97.6 97.9 N/C
CL (mlday
 1kg
 1) 4.8170.41 5.6670.46 0.1726
Cmax (mgml
 1) 392727 819777 N/A
Cmax/dose (kgml
 1) 0.03970.003 0.04170.004 0.7124
t1/2, a (days) 0.14870.033 0.10770.033 0.3829
t1/2, b (days) 8.7171.1 6.9070.89 0.2054
MRT (days) 12.371.5 9.7671.2 0.1908
Vi (mlkg
 1) 25.571.8 24.472.4 0.7077
Vss (mlkg
 1) 59.073.1 55.373.6 0.4390
AUC¼area under the curve; % AUCb¼percent of AUC in beta phase;
CL¼clearance; Cmax¼maximum concentration; t1/2, a,¼half-life of the alpha phase;
t1/2, b¼half-life of the beta phase; MRT¼mean residence time; Vi¼initial volume
of distribution; Vss¼steady-state volume of distribution; N/C¼not calculated;
N/A¼not available.
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sbound to TRAIL-R1, and potently induced apoptosis in vitro
in a broad range of human tumour cell types via activation of
both intrinsic and extrinsic signalling cascades. HGS-ETR1 had
an effective pharmacokinetic half-life, and induced rapid
tumour regression in multiple xenograft tumour models alone
and in combination with chemotherapeutic agents. These data
indicate that HGS-ETR1 has significant potential as a cancer
therapeutic agent. HGS-ETR1 is currently being evaluated in Phase
I/II clinical trials in patients with advanced solid or haematological
tumours.
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